Life Biosciences

Life Biosciences, Inc.

is a Boston-based biopharmaceutical company focused on developing therapies that aim to extend healthy human lifespan by addressing the biological causes of aging. Founded in 2017 by Harvard Medical School professor David Sinclair and co-founder Tristan Edwards, the company operates as a biotech platform dedicated to cellular rejuvenation. Life Biosciences has raised approximately $175 million in funding, including an $80 million Series D round in April 2026. The company employs a multi-platform approach targeting the biology of aging, with key areas including epigenetic reprogramming, chaperone-mediated autophagy, and mitochondrial uncoupling. Its lead investigational drug, ER-100, has received FDA clearance for clinical trials to treat optic neuropathies, including glaucoma. Life Biosciences also develops therapeutic candidates for neurodegenerative diseases and conducts extensive preclinical research to validate its technologies. The company serves patients with age-related diseases, healthcare providers, and even the veterinary market, aiming to improve healthspan across various sectors.